Lombard Odier Asset Management Europe Ltd lessened its position in Danaher Corporation (NYSE:DHR – Free Report) by 54.5% in the 1st quarter, Holdings Channel reports. The firm owned 26,109 shares of the conglomerate’s stock after selling 31,312 shares during the period. Lombard Odier Asset Management Europe Ltd’s holdings in Danaher were worth $4,950,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently made changes to their positions in DHR. Main Street Group LTD acquired a new position in shares of Danaher in the 1st quarter valued at $25,000. JPL Wealth Management LLC acquired a new stake in Danaher during the 3rd quarter worth $25,000. Elevated Capital Advisors LLC bought a new position in Danaher during the fourth quarter worth about $26,000. WFA of San Diego LLC bought a new position in Danaher during the second quarter worth about $26,000. Finally, Hilton Head Capital Partners LLC acquired a new position in Danaher in the fourth quarter valued at about $27,000. 79.05% of the stock is owned by institutional investors.
Danaher Stock Performance
DHR opened at $191.87 on Friday. The company has a market capitalization of $134.88 billion, a price-to-earnings ratio of 34.08, a P/E/G ratio of 2.38 and a beta of 0.79. The business’s 50-day moving average price is $185.64 and its two-hundred day moving average price is $197.04. Danaher Corporation has a 1 year low of $160.93 and a 1 year high of $242.80. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.52.
Danaher Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Friday, June 26th will be paid a $0.40 dividend. The ex-dividend date is Friday, June 26th. This represents a $1.60 annualized dividend and a yield of 0.8%. Danaher’s payout ratio is presently 28.42%.
Analysts Set New Price Targets
Several brokerages have issued reports on DHR. The Goldman Sachs Group lowered their price target on Danaher from $265.00 to $230.00 and set a “buy” rating for the company in a report on Monday, April 13th. Royal Bank Of Canada boosted their price objective on Danaher from $200.00 to $215.00 and gave the company an “outperform” rating in a research report on Wednesday. Citigroup started coverage on Danaher in a research note on Tuesday, May 26th. They set a “buy” rating and a $230.00 target price for the company. Morgan Stanley dropped their target price on shares of Danaher from $270.00 to $255.00 and set an “overweight” rating on the stock in a report on Wednesday, April 22nd. Finally, HSBC cut their price target on shares of Danaher from $270.00 to $230.00 and set a “buy” rating on the stock in a research note on Wednesday, June 3rd. One investment analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and a consensus price target of $228.91.
Read Our Latest Research Report on DHR
Danaher News Summary
Here are the key news stories impacting Danaher this week:
- Positive Sentiment: J.P. Morgan reiterated a Buy rating on Danaher, which may help support investor confidence after the post-earnings pullback. J.P. Morgan Keeps Their Buy Rating on Danaher (DHR)
- Positive Sentiment: Several articles argue Danaher’s recent slump looks like an overreaction and could be a buying opportunity, suggesting the stock may recover if investors refocus on its long-term fundamentals. Here’s Why the Slump in Danaher Stock This Week Looks Like a Buying Opportunity
- Positive Sentiment: Danaher’s quarterly results beat estimates, with EPS of $1.94 versus $1.85 expected and revenue of $6.27 billion above forecasts, which supports the case that core business performance remains solid. The ‘Standout Performance’ That Could Save Thermo Fisher, Danaher And Others
- Neutral Sentiment: Billionaire investor Dan Loeb reduced his Danaher stake in Q1 2026, adding to sentiment pressure around life sciences tools stocks, though it does not change Danaher’s operating results. Billionaire Investor Dumps Thermo Fisher, Cuts Danaher As He Pares Life Sciences Tools Bets
- Neutral Sentiment: Danaher saw unusually heavy put option activity, signaling traders are hedging against more downside in the near term. Don’t Quit on Danaher Stock After Horrific Earnings Reaction
Danaher Profile
Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.
Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.
Featured Articles
- Five stocks we like better than Danaher
- Telecom Earnings Reveal a Sector That Finally Looks Healthier
- Defense Earnings Show Readiness Now and Modernization Ahead
- Why Palantir Investors Aren’t Panicking While the Rest of AI Sells Off
- MarketBeat Week in Review – 07/20- 07/24
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.
